share_log

Plus Therapeutics Has Completed Of Enrollment In Cohort 2 Of The Respect-LM Phase 1/2a Dose Escalation Trial Of Rhenium (186Re) Obisbemeda For Leptomeningeal Metastases

Plus Therapeutics Has Completed Of Enrollment In Cohort 2 Of The Respect-LM Phase 1/2a Dose Escalation Trial Of Rhenium (186Re) Obisbemeda For Leptomeningeal Metastases

Plus 治療藥物已經完成了隊列 2 的 Rhenium(186Re)針對 leptomeningeal 轉移酶的相關 LM 期 1/2a 劑量升級試驗的註冊
Benzinga Real-time News ·  2023/02/01 07:14

The company said the next steps, following the Data and Safety Monitoring Board review anticipated next month, will be completing enrollment in Phase 1/Part A, followed by a meeting with the FDA to consider dose expansion in the Phase 1/Part B trial. Additionally, initial data from Phase 1/Part A is anticipated in 2H of 2023.

該公司表示,在下個月預計的數據和安全監控委員會審查之後,下一步將完成第 1 階段 A 部分的註冊,然後與 FDA 會議考慮在第 1 階段/部分 B 試驗中擴展劑量。此外,預計第 1 階段/A 部分的初始數據將在 2023 年下半年。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論